Anika Therapeutics | ANIK - Ebitda

Stock Price
14.47
Daily Change
0.11 0.77%
Monthly
38.34%
Yearly
-14.88%
Q1 Forecast
13.92

Anika Therapeutics reported $-2.69M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Anika Therapeutics USD -2.69M 4.73M Mar/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -314.19M 31.48M Dec/2025
Integra LifeSciences USD 104.21M 25.76M Dec/2025
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 9.52B 389M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merit Medical Systems USD 97.23M 17.69M Dec/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sanofi EUR 4.84B 2.95B Sep/2025
Smith & Nephew USD 796M 139M Dec/2025
Stryker USD 1.67B 206M Sep/2025
Surmodics USD 1.53M 485K Sep/2024
Veracyte USD 42.31M 2.58M Dec/2025
Xencor USD -51.05M 55.28M Dec/2025
Zimmer Biomet Holdings USD 759M 120.8M Dec/2025